Clinical Trial Update: Effect of Empagliflozin in Patients With eGFR Between 10 and 20 ml/Min/1.73m2 [Phase 4]

View source ↗

Summary

This is a Phase 4 trial evaluating empagliflozin in patients with very low eGFR (10-20 mL/min/1.73m2) that is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Empagliflozin (empagliflozin)

Snippet

Sponsor: Centre Hospitalier Universitaire de Nice | Conditions: Chronic Kidney Diseases | Phase 4 | Status: NOT_YET_RECRUITING